Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Coval Biopharma (Shanghai) Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these matters are concentrated within 1 distinct art unit, which indicates a very narrow and specific technical focus for the company's current patent filings. This concentration in 1 distinct art unit can be advantageous, as it allows the company to develop a deep understanding of the specific examination trends and prior art preferences of that particular unit. The 2 pending office actions represent a focused effort to secure intellectual property in the Biotechnology & Pharmaceuticals sector.
The prosecution of these cases is handled by 2 distinct examiners, creating a scenario where each examiner is responsible for a single application. SHIAO, YIH-HORNG is the busiest examiner for the portfolio, currently managing 1 pending office action. With 2 distinct examiners covering the 2 pending office actions, the company receives feedback from multiple sources despite the technical concentration in 1 distinct art unit. This distribution means that the company's success will depend on the individual discretion of 2 different patent office employees within the same technical field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, YIH-HORNG | 1 | 72.6% | +75.9% |
| BRANDSEN, BENJAMIN MICHAEL | 1 | 60.9% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692340 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | SHIAO, YIH-HORNG | — |
| 18005356 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | BRANDSEN, BENJAMIN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692340 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | SHIAO, YIH-HORNG | — |
| 18005356 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | BRANDSEN, BENJAMIN MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692340 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | SHIAO, YIH-HORNG | — | §102§103Other | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18005356 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103§112Other | Final Rejection | — | Pending | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCoval Biopharma (Shanghai) Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Yih-Horng Shiao has the most, with 1 of Coval Biopharma (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
